NCT03656354 (SCG-HF) is a clinical trial of Seismocardiography in Heart Failure, sponsored by Acarix.

Who is sponsoring NCT03656354?

NCT03656354 is sponsored by Acarix.

What drugs are being tested in NCT03656354?

Interventions in NCT03656354: Seismocardiography.

What condition does NCT03656354 study?

NCT03656354 studies Heart Failure.

Is NCT03656354 still recruiting?

NCT03656354 is currently completed. Last updated 28 February 2023.

Last reviewed 2023-02-28 · How we verify

NCT03656354: SCG-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of Heart Failure Patients by Seismocardiography

Completed Last updated 28 February 2023

What this trial tests

trial testing Seismocardiography in Heart Failure in 219 participants. Completed in 27 July 2022.

Timeline

29 June 2018

Primary endpoint
27 July 2022

27 July 2022

Quick facts

Lead sponsor	Acarix
Status	Completed
Study type	OBSERVATIONAL
Enrollment	219
Start date	29 June 2018
Primary completion	27 July 2022
Estimated completion	27 July 2022
Sites	2 locations across Denmark

Drugs / interventions tested

Seismocardiography

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Acarix

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the current study is to develop and validate an algorithm based on seismocardiography recordings to detect heart failure. Echocardiography will be used as the golden standard for defining patients with heart failure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03656354 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Acarix
Last refreshed: 28 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03656354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing